Improving antibody-drug therapy for acute myeloid leukemia
Official title: Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia
Funded at State University of New York at Buffalo · NIH-11006313 · Data updated 2026-11-12
This study is looking for better and safer ways to treat people with acute myeloid leukemia (AML) by developing new targeted therapies that focus on cancer cells while reducing side effects for healthy ones.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $427,572 |
| NIH project number | 5R01CA275967-03 |
| Project ID | NIH-11006313 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia who are seeking advanced therapeutic options.
✕Less likely to help
Patients with other types of leukemia or those who do not have acute myeloid leukemia may not benefit from this research.
What this research studies
This research focuses on enhancing the safety and effectiveness of antibody-drug conjugate (ADC) therapy for patients with acute myeloid leukemia (AML). It involves creating new monoclonal antibodies and nanobodies that specifically target proteins overexpressed in AML cells. The study will also explore innovative strategies to reduce side effects by using bispecific constructs and payload binding selectivity enhancers, which aim to minimize toxicity to healthy tissues while effectively targeting cancer cells. Through these approaches, the research seeks to optimize treatment outcomes for AML patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with acute myeloid leukemia.
How similar studies have gone: Previous research has shown promise in using targeted therapies for leukemia, suggesting that this approach could yield significant advancements.
Where this research is happening
-
State University of New York at Buffalo
Amherst, United States Active
Researchers
- Principal investigator: Balthasar, Joseph P — State University of New York at Buffalo
- Study coordinator: Balthasar, Joseph P
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.